Rejected
at 5:48 p.m. Aug, 11, 2024 ]
by
Ahmed7
Author:
carolinem3466
Type of change:
Content error
Rationale for change
medication decisions (and any medical decisions) should not be made based on race alone, race is also not the same as ancestry which is only occasionally relevant to condition prevalences in certain communities
Rejection reason
comments
Current
Suggested
Text
Text
Text
Text
Extra
- Beta-blockers, RAAS inhibitors (ACEIs/ARBs/ARNIs), SGLT-2 inhibitors, and MRAs are part of Guideline-Directed Medical Therapy (GDMT) for heart failure (improve both survival and hospitalization rates)
- SGLT-2 inhibitors decrease risk of cardiovascular death or hospitalization for heart failure, regardless of the presence or absence of diabetes (EMPEROR-Reduced trial)
- Diuretics provide symptomatic relief for volume overload but no mortality benefit
- Digoxin reduces hospitalizations but offers no mortality benefit

Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy



Watch Beta Blockers




Watch Sacubitril-Valsartan, Milrinone, Nesiritide, Ivabradine



Watch K+ Sparing Diuretics







Watch Primary Hypertension & Hypertensive Emergency



Watch Beta Blockers




Watch Sacubitril-Valsartan, Milrinone, Nesiritide, Ivabradine



Watch K+ Sparing Diuretics








Sketchy 2







Watch Chronic Heart Failure Management Part 1




Watch Chronic Heart Failure Management Part 2




Watch Diabetes Management




Watch Hypertension Management



Watch Post-ACS Management







Watch Chronic Heart Failure Management Part 1




Watch Chronic Heart Failure Management Part 2




Watch Diabetes Management




Watch Hypertension Management



Watch Post-ACS Management
Sketchy Extra
Empty field
Picmonic
Empty field
Physeo
Empty field
Bootcamp
Empty field
OME
Additional Resources

Emma Holiday:

Emma Holiday:

One by one
Empty field










